Treatment Of Complement Mediated Disorders

Cambridge Enterprise Limited
Granted App No 201847045500 Patent 537067 Biotechnology

Patent information

IP India · live record
Application number
201847045500
Filing date
03 December 2018
Status
Granted
Legal status
Inforce
Publication number
08/2019
Publication type
INA
Invention field
Biotechnology
Patent number
537067
Grant date
07 May 2024
Next renewal due
03 May 2026Overdue

Abstract

Methods of treatment of complement-mediated disorders in particular disorders associated with over-activity of the complement C3b feedback cycle (for example age-related macular degeneration (AMD)) using gene therapy is described. According to the methods levels of complement Factor I are elevated by administration of a recombinant viral vector encoding Factor I such that a therapeutically effective amount of the encoded Factor I is expressed from the vector in the subject. Recombinant viral vectors encoding Factor I recombinant virus particles encapsidating the vectors and their use in the methods of treatment is also described.

Applicants

2
U.K.
CAMBRIDGE ENTERPRISE LIMITED The Old Schools Trinity Lane Cambridge Cambridgeshire CB2 1TN
Australia
THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD) (incorporating The Royal Alexandra Hospital For Children) Cnr Hawkesbury Road and Hainsworth Street Westmead, New South Wales

Inventors

2
U.K.
LACHMANN, PeterDepartment of Veterinary Medicine University of Cambridge Madingley Road Cambridge Cambridgeshire CB3 0ES
Australia
ALEXANDER, IanChildren's Medical Research Institute 214 Hawkesbury Road Westmead Sydney, New South Wales 2145

Claims

52
1 A method for preventing, treating, or ameliorating a complement-mediated disorder in a subject in need thereof, which comprises administering to the subject a recombinant viral vector comprising nucleic acid encoding Factor I, or a fragment or derivative thereof that retains C3b-inactivating and iC3b-degradation activity, such that a therapeutically effective amount of the encoded Factor ls or the fragment or derivative thereof, is expressed from the nucSeic acid in the subject, thereby increasing the level of C3b~inactivating and iC3b~ degradation activity in the subject.
2 A method according to claim 1, wherein the level of C3b-inactivating and iC3b» degradation activity in the subject is increased to a level that exceeds a normal level.
3 A method according to claim 1 or claim 2, wherein the subject is administered with a recombinant virus particle that encapsidates the recombinant viral vector.
4 A method according to claim 3S wherein the recombinant virus particle infects the liver of the subject following administration, resulting in expression of the Factor ls or the fragment or derivative thereof, from the liver.
5 A method according to claim 3 or 4P wherein the recombinant virus particle is a recombinant adeno-associated virus (rAAV) particle encapsidating a rAAV vector,
6 A method according to claim 5, wherein the rAAV particle is pseudotyped to confer liver tropism,
7 A method according to claim 5 or 6, wherein the rAAV particle comprises one or two AAV2 ITRs, or derivatives thereof wherein each derivative AAV2 ITR comprises nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length with the nucleotide sequence of a naturally occurring AAV2 ITR, and wherein the rAAV particle is pseudotyped with AAV8 capsid protein (rAAV2/8), or AAV2 pseudotyped with AAV9 capsid protein (rAAV2/9), or a derivative thereof comprising amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%s or 99% identical over its entire length to the amino acid sequence of a naturally occurring AAV8 or AAV9 capsid protein.
8 A method according to any preceding claim, wherein the recombinant virus particle is administered intravenously to the subject.
9 A method according to any preceding cSaim, wherein the recombinant virai vector is a non-integrating, episomal vira! vector.
10 A method according to any preceding claim, wherein the encoded Factor !, or the fragment or derivative thereof, is expressed from a iiver-specific promoter, such as a human a!pha-1-anti~trypsin (hAAT) promoter.
11 A method according to any preceding claim, wherein the leve! of C3b-inacfivating and iC3b-degradation activity in the subject is increased to a level that is up to twice the norma! level.
12 A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is up to 80%, or up to 60%, above the normal level.
13 A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is up to 40%, or up to 20% above the normal level.
14 A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is at least 5%, 10%, 15%, 20%, or 25% above the normal level.
15 A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is the level in serum of the subject.
16 A method according to any preceding claim, wherein the normal level of C3b-inactivating and iC3b-degradation activity in the subject is equivalent to that provided by 30-40jug/ml Factor I in serum of the subject.
17 A method according to any preceding claim, wherein the complement-mediated disorder is a disorder associated with over-activity of the complement C3b feedback cycle.
18 A method according to any preceding claim, wherein the complement-mediated disorder is age-related macular degeneration (AMD) (particularly early (dry) AMD, or geographic atrophy), dense deposit disease (DDD), atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathies, membranoproliferative glomerulonephritis Type 2 (MPGN2), atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, paroxysmal nocturnal haemoglobinuria (PNH), inflammatory or autoinflammatory diseases of old age, membranoproliferative glomerulonephritis type i (MPGN type I), membranoproliferative glomerulonephritis type III (MPGN type III), Guiliain-Barre syndrome, Henoch-Schonlein purpura, IgA nephropathy, or membranous glomerulonephritis.
19 A method according to claim 18, wherein the subject is at risk of developing AMD,
20 A method according to claim 19, wherein the subject is homozygous or heterozygous susceptible for one or more SNPs associated with AMD.
21 A method according to claim 19 or 20, which further comprises determining whether the subject is at risk of developing AMD.
22 A method according to claim 21, wherein it is determined whether the subject is at risk of developing AMD by determining whether the subject is homozygous or heterozygous susceptible for one or more SNPs associated with AMD.
23 A method according to claim 20 or 22, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is at least 10% above the normal level if the subject is heterozygous susceptible for one or more SNPs associated with AMD.
24 A method according to claim 20 or 22, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is at least 50% above the norma! level if the subject is homozygous susceptible for one or more SNPs associated with AMD.
25 A method according to any preceding claim, which further comprises determining the level of C3b-inactivating and iC3b-degradation activity in the subject at least a week after the administration, and repeating the administration if the level of activity is found to be at, or below the normal level.
26 A method according to any preceding claim, wherein the Factor! is human Factor I with an amino acid sequence of SEQ ID NO: 2 or 4.
27 A method according to any preceding claim, wherein the fragment or derivative of Factor I is a polypeptide that has at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid identity across its entire length to human Factor I with an amino acid sequence of SEQ ID NO: 2 or 4.
28 A method according to any preceding claim, wherein the subject is a human subject.
29 A recombinant viral vector which comprises nucleic acid encoding Factor I, or a fragment or derivative thereof that retains C3b-inactivating and iC3b-degradation activity.
30 A recombinant viral vector according to claim 29, which is a non-integrating, episomal viral vector.
31 A recombinant viral vector according to claim 29 or 30, wherein the nucleic acid encoding Factor I, or the fragment or derivative thereof, is operably linked to a promoter.
32 A recombinant viral vector according to claim 31, wherein the promoter is a liver-specific promoter, such as a human alpha-1-anti-trypsin (hAAT) promoter.
33 A recombinant viral vector according to any of claims 28 to 31, which is a recombinant adeno-associated virus (rAAV) vector.
34 A recombinant viral vector according to claim 33, which comprises an expression cassette flanked by AAV inverted terminal repeats (ITRs), wherein the expression cassette comprises the nucleic acid encoding Factor I, or the fragment or derivative thereof, operably linked to a promoter and a polyadenylation recognition site.
35 A recombinant viral vector according to claim 34, wherein the ITRs are AAV2 ITRs, or derivatives thereof, wherein each derivative AAV2 ITR comprises nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length with the nucleotide sequence of a naturally occurring AAV2 ITR.
36 A recombinant virus particle, which comprises a viral capsid encapsidating a recombinant viral vector according to any of claims 29 to 35.
37 A recombinant virus particle according to claim 28 or 29 which is capable of transducing liver cells, particularly hepatocytes.
38 A recombinant virus particle according to claim 36 or 37, which is a rAAV particle,
39 A recombinant virus particle according to claim 38, wherein the rAAV particle is pseudotyped to confer liver tropism.
40 A recombinant virus particle according to claim 38 or 39, wherein the rAAV particle comprises AAV8 or AAV9 capsid protein, or a derivative thereof comprising amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length to the amino acid sequence of a naturally occurring AAV8 or AAV9 capsid protein.
41 A recombinant virus particle according to claim 40, wherein the rAAV particle comprises one or two AAV2 ITRs, or derivatives thereof wherein each derivative AAV2 ITR comprises nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length with the nucleotide sequence of a naturally occurring AAV2 ITR.
42 A pharmaceutical composition, which comprises: a recombinant viral vector according to any of claims 29 to 35, or a recombinant virus particle according to any of claims 36 to 41; and a pharmaceutical^ acceptable carrier, excipient, or diluent.
43 A pharmaceutical composition according to claim 42, which is suitable for intravenous administration.
44 A kit, which comprises: a recombinant viral vector according to any of claims 29 to 35, or a recombinant virus particle according to any of claims 36 to 41; and a pharmaceutical^ acceptable carrier, excipient, or diluent.
45 A kit for production of rAAV particles, which comprises: a rAAV vector according to any of claims 33 to 35; and one or more helper plasmids comprising nucleic acid encoding AAV replication and capsid proteins, and genes required for a productive AAV life cycle.
46 A kit according to claim 45, which comprises a first helper plasmid comprising the nucleic acid encoding AAV replication and capsid proteins, and a second helper plasmid comprising the nucleic acid encoding genes required for a productive AAV life cycle.
47 A recombinant viral vector according to any of claims 29 to 35, a recombinant virus particle according to any of claims 36 to 41, or a pharmaceutical composition according to claim 42 or 43, for use as a medicament.
48 A recombinant viral vector according to any of claims 29 to 35, a recombinant virus particle according to any of claims 36 to 41, or a pharmaceutical composition according to claim 41 or 42, for use in the treatment of a complement-mediated disorder.
49 Use of a recombinant viral vector according to any of claims 29 to 35, a recombinant virus particle according to any of claims 36 to 41, or a pharmaceutical composition according to ciaim 42 or 43, in the manufacture of a medicament for the treatment of a complement-mediated disorder.
50 A vector, particie, or composition according to ciaim 48, or use according to ciaim 48, wherein the complement-mediated disorder is a disorder associated with over-activity of the compiement C3b feedback cycle.
51 A vector, particie, or composition according to claim 50, wherein the complement-mediated disorder is age-reiated macular degeneration (AMD) (particularly early (dry) AMD, or geographic atrophy), dense deposit disease (DDD), atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathies, membranoproliferative glomerulonephritis Type 2 (MPGN2), atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, paroxysmal nocturnal haemoglobinuria (PNH), inflammatory or autoinflammatorys disease of old age, membranoproliferative glomerulonephritis type I (MPGN type I), membranoproliferative glomerulonephritis type III (MPGN type III), Guillain-Barre syndrome, Henoch-Schonlein purpura, IgA nephropathy, or membranous glomerulonephritis.
52 A vector, particle, or composition according to claim 50, wherein the complement-mediated disorder is age-related macular degeneration (AMD).

Specification

Show full textCollapse

We Claim: 1. A method for preventing, treating, or ameliorating a complement-mediated disorder in a subject in need thereof, which comprises administering to the subject a recombinant viral vector comprising nucleic acid encoding Factor I, or a fragment or derivative thereof that retains C3b-inactivating and iC3b-degradation activity, such that a therapeutically effective amount of the encoded Factor ls or the fragment or derivative thereof, is expressed from the nucSeic acid in the subject, thereby increasing the level of C3b~inactivating and iC3b~ degradation activity in the subject. 2. A method according to claim 1, wherein the level of C3b-inactivating and iC3b» degradation activity in the subject is increased to a level that exceeds a normal level. 3. A method according to claim 1 or claim 2, wherein the subject is administered with a recombinant virus particle that encapsidates the recombinant viral vector. 4. A method according to claim 3S wherein the recombinant virus particle infects the liver of the subject following administration, resulting in expression of the Factor ls or the fragment or derivative thereof, from the liver. 5. A method according to claim 3 or 4P wherein the recombinant virus particle is a recombinant adeno-associated virus (rAAV) particle encapsidating a rAAV vector, 6. A method according to claim 5, wherein the rAAV particle is pseudotyped to confer liver tropism, 7. A method according to claim 5 or 6, wherein the rAAV particle comprises one or two AAV2 ITRs, or derivatives thereof wherein each derivative AAV2 ITR comprises nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length with the nucleotide sequence of a naturally occurring AAV2 ITR, and wherein the rAAV particle is pseudotyped with AAV8 capsid protein (rAAV2/8), or AAV2 pseudotyped with AAV9 capsid protein (rAAV2/9), or a derivative thereof comprising amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%s or 99% identical over its entire length to the amino acid sequence of a naturally occurring AAV8 or AAV9 capsid protein. 8. A method according to any preceding claim, wherein the recombinant virus particle is administered intravenously to the subject.

9. A method according to any preceding cSaim, wherein the recombinant virai vector is a non-integrating, episomal vira! vector. 10. A method according to any preceding claim, wherein the encoded Factor !, or the fragment or derivative thereof, is expressed from a iiver-specific promoter, such as a human a!pha-1-anti~trypsin (hAAT) promoter. 11. A method according to any preceding claim, wherein the leve! of C3b-inacfivating and iC3b-degradation activity in the subject is increased to a level that is up to twice the norma! level. 12. A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is up to 80%, or up to 60%, above the normal level. 13. A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is up to 40%, or up to 20% above the normal level. 14. A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is at least 5%, 10%, 15%, 20%, or 25% above the normal level. 15. A method according to any preceding claim, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is the level in serum of the subject. 16. A method according to any preceding claim, wherein the normal level of C3b-inactivating and iC3b-degradation activity in the subject is equivalent to that provided by 30-40jug/ml Factor I in serum of the subject. 17. A method according to any preceding claim, wherein the complement-mediated disorder is a disorder associated with over-activity of the complement C3b feedback cycle. 18. A method according to any preceding claim, wherein the complement-mediated disorder is age-related macular degeneration (AMD) (particularly early (dry) AMD, or geographic atrophy), dense deposit disease (DDD), atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathies, membranoproliferative glomerulonephritis Type 2 (MPGN2), atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis,

paroxysmal nocturnal haemoglobinuria (PNH), inflammatory or autoinflammatory diseases of old age, membranoproliferative glomerulonephritis type i (MPGN type I), membranoproliferative glomerulonephritis type III (MPGN type III), Guiliain-Barre syndrome, Henoch-Schonlein purpura, IgA nephropathy, or membranous glomerulonephritis. 19. A method according to claim 18, wherein the subject is at risk of developing AMD, 20. A method according to claim 19, wherein the subject is homozygous or heterozygous susceptible for one or more SNPs associated with AMD. 21. A method according to claim 19 or 20, which further comprises determining whether the subject is at risk of developing AMD. 22. A method according to claim 21, wherein it is determined whether the subject is at risk of developing AMD by determining whether the subject is homozygous or heterozygous susceptible for one or more SNPs associated with AMD. 23. A method according to claim 20 or 22, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is at least 10% above the normal level if the subject is heterozygous susceptible for one or more SNPs associated with AMD. 24. A method according to claim 20 or 22, wherein the level of C3b-inactivating and iC3b-degradation activity in the subject is increased to a level that is at least 50% above the norma! level if the subject is homozygous susceptible for one or more SNPs associated with AMD. 25. A method according to any preceding claim, which further comprises determining the level of C3b-inactivating and iC3b-degradation activity in the subject at least a week after the administration, and repeating the administration if the level of activity is found to be at, or below the normal level. 26. A method according to any preceding claim, wherein the Factor! is human Factor I with an amino acid sequence of SEQ ID NO: 2 or 4. 27. A method according to any preceding claim, wherein the fragment or derivative of Factor I is a polypeptide that has at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% amino acid identity across its entire length to human Factor I with an amino acid sequence of SEQ ID NO: 2 or 4. 28. A method according to any preceding claim, wherein the subject is a human subject.

29. A recombinant viral vector which comprises nucleic acid encoding Factor I, or a fragment or derivative thereof that retains C3b-inactivating and iC3b-degradation activity. 30. A recombinant viral vector according to claim 29, which is a non-integrating, episomal viral vector. 31. A recombinant viral vector according to claim 29 or 30, wherein the nucleic acid encoding Factor I, or the fragment or derivative thereof, is operably linked to a promoter. 32. A recombinant viral vector according to claim 31, wherein the promoter is a liver-specific promoter, such as a human alpha-1-anti-trypsin (hAAT) promoter. 33. A recombinant viral vector according to any of claims 28 to 31, which is a recombinant adeno-associated virus (rAAV) vector. 34. A recombinant viral vector according to claim 33, which comprises an expression cassette flanked by AAV inverted terminal repeats (ITRs), wherein the expression cassette comprises the nucleic acid encoding Factor I, or the fragment or derivative thereof, operably linked to a promoter and a polyadenylation recognition site. 35. A recombinant viral vector according to claim 34, wherein the ITRs are AAV2 ITRs, or derivatives thereof, wherein each derivative AAV2 ITR comprises nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length with the nucleotide sequence of a naturally occurring AAV2 ITR. 36. A recombinant virus particle, which comprises a viral capsid encapsidating a recombinant viral vector according to any of claims 29 to 35. 37. A recombinant virus particle according to claim 28 or 29 which is capable of transducing liver cells, particularly hepatocytes. 38. A recombinant virus particle according to claim 36 or 37, which is a rAAV particle, 39. A recombinant virus particle according to claim 38, wherein the rAAV particle is pseudotyped to confer liver tropism. 40. A recombinant virus particle according to claim 38 or 39, wherein the rAAV particle comprises AAV8 or AAV9 capsid protein, or a derivative thereof comprising amino acid sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over

its entire length to the amino acid sequence of a naturally occurring AAV8 or AAV9 capsid protein. 41. A recombinant virus particle according to claim 40, wherein the rAAV particle comprises one or two AAV2 ITRs, or derivatives thereof wherein each derivative AAV2 ITR comprises nucleotide sequence that is at least 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% identical over its entire length with the nucleotide sequence of a naturally occurring AAV2 ITR. 42. A pharmaceutical composition, which comprises: a recombinant viral vector according to any of claims 29 to 35, or a recombinant virus particle according to any of claims 36 to 41; and a pharmaceutical^ acceptable carrier, excipient, or diluent. 43. A pharmaceutical composition according to claim 42, which is suitable for intravenous administration. 44. A kit, which comprises: a recombinant viral vector according to any of claims 29 to 35, or a recombinant virus particle according to any of claims 36 to 41; and a pharmaceutical^ acceptable carrier, excipient, or diluent. 45. A kit for production of rAAV particles, which comprises: a rAAV vector according to any of claims 33 to 35; and one or more helper plasmids comprising nucleic acid encoding AAV replication and capsid proteins, and genes required for a productive AAV life cycle. 46. A kit according to claim 45, which comprises a first helper plasmid comprising the nucleic acid encoding AAV replication and capsid proteins, and a second helper plasmid comprising the nucleic acid encoding genes required for a productive AAV life cycle. 47. A recombinant viral vector according to any of claims 29 to 35, a recombinant virus particle according to any of claims 36 to 41, or a pharmaceutical composition according to claim 42 or 43, for use as a medicament. 48. A recombinant viral vector according to any of claims 29 to 35, a recombinant virus particle according to any of claims 36 to 41, or a pharmaceutical composition according to claim 41 or 42, for use in the treatment of a complement-mediated disorder. 49. Use of a recombinant viral vector according to any of claims 29 to 35, a recombinant virus particle according to any of claims 36 to 41, or a pharmaceutical composition according

to ciaim 42 or 43, in the manufacture of a medicament for the treatment of a complement-mediated disorder. 50. A vector, particie, or composition according to ciaim 48, or use according to ciaim 48, wherein the complement-mediated disorder is a disorder associated with over-activity of the compiement C3b feedback cycle. 51. A vector, particie, or composition according to claim 50, wherein the complement-mediated disorder is age-reiated macular degeneration (AMD) (particularly early (dry) AMD, or geographic atrophy), dense deposit disease (DDD), atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathies, membranoproliferative glomerulonephritis Type 2 (MPGN2), atherosclerosis, chronic cardiovascular disease, Alzheimer's disease, systemic vasculitis, paroxysmal nocturnal haemoglobinuria (PNH), inflammatory or autoinflammatorys disease of old age, membranoproliferative glomerulonephritis type I (MPGN type I), membranoproliferative glomerulonephritis type III (MPGN type III), Guillain-Barre syndrome, Henoch-Schonlein purpura, IgA nephropathy, or membranous glomerulonephritis. 52. A vector, particle, or composition according to claim 50, wherein the complement-mediated disorder is age-related macular degeneration (AMD).

Documents

Sign in to open
Application documents
1 201847045500.pdf 03 Dec 2018
2 201847045500-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-12-2018(online)].pdf 03 Dec 2018
3 201847045500-STATEMENT OF UNDERTAKING (FORM 3) [03-12-2018(online)].pdf 03 Dec 2018
4 201847045500-SEQUENCE LISTING(PDF) [03-12-2018(online)].pdf 03 Dec 2018
5 201847045500-SEQUENCE LISTING [03-12-2018(online)].txt 03 Dec 2018
6 201847045500-PRIORITY DOCUMENTS [03-12-2018(online)].pdf 03 Dec 2018
7 201847045500-FORM 1 [03-12-2018(online)].pdf 03 Dec 2018
8 201847045500-DRAWINGS [03-12-2018(online)].pdf 03 Dec 2018
9 201847045500-DECLARATION OF INVENTORSHIP (FORM 5) [03-12-2018(online)].pdf 03 Dec 2018
10 201847045500-COMPLETE SPECIFICATION [03-12-2018(online)].pdf 03 Dec 2018
11 201847045500-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [03-12-2018(online)].pdf 03 Dec 2018
12 201847045500-Proof of Right (MANDATORY) [12-04-2019(online)].pdf 12 Apr 2019
13 201847045500-FORM-26 [12-04-2019(online)].pdf 12 Apr 2019
14 Correspondence by Agent_Form-1 And Power of Attorney_15-04-2019.pdf 15 Apr 2019
15 201847045500-FORM 3 [03-06-2019(online)].pdf 03 Jun 2019
16 201847045500-FORM 3 [09-03-2020(online)].pdf 09 Mar 2020
17 201847045500-FORM 18 [22-04-2020(online)].pdf 22 Apr 2020
18 201847045500-FORM 3 [04-03-2021(online)].pdf 04 Mar 2021
19 201847045500-FER.pdf 07 Sep 2022
20 201847045500-FORM 4(ii) [28-02-2023(online)].pdf 28 Feb 2023
21 201847045500-PETITION UNDER RULE 137 [05-06-2023(online)].pdf 05 Jun 2023
22 201847045500-OTHERS [05-06-2023(online)].pdf 05 Jun 2023
23 201847045500-FORM 3 [05-06-2023(online)].pdf 05 Jun 2023
24 201847045500-FER_SER_REPLY [05-06-2023(online)].pdf 05 Jun 2023
25 201847045500-COMPLETE SPECIFICATION [05-06-2023(online)].pdf 05 Jun 2023
26 201847045500-CLAIMS [05-06-2023(online)].pdf 05 Jun 2023
27 201847045500-US(14)-HearingNotice-(HearingDate-21-03-2024).pdf 22 Feb 2024
28 201847045500-US(14)-ExtendedHearingNotice-(HearingDate-22-04-2024).pdf 18 Mar 2024
29 201847045500-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [18-03-2024(online)].pdf 18 Mar 2024
30 201847045500-FORM-26 [18-04-2024(online)].pdf 18 Apr 2024
31 201847045500-Correspondence to notify the Controller [18-04-2024(online)].pdf 18 Apr 2024
32 201847045500-Written submissions and relevant documents [06-05-2024(online)].pdf 06 May 2024
33 201847045500-Retyped Pages under Rule 14(1) [06-05-2024(online)].pdf 06 May 2024
34 201847045500-Annexure [06-05-2024(online)].pdf 06 May 2024
35 201847045500-Annexure [06-05-2024(online)]-1.pdf 06 May 2024
36 201847045500-2. Marked Copy under Rule 14(2) [06-05-2024(online)].pdf 06 May 2024
37 201847045500-PatentCertificate07-05-2024.pdf 07 May 2024
38 201847045500-IntimationOfGrant07-05-2024.pdf 07 May 2024
Search strategy
1searchhistoryE_06-09-2022.pdf

ERegister / renewals

Inforce
3rd Renewed 03 Jun 2024 Period 03 May 2019 – 03 May 2020 · CBR 36595 · Certificate 108225 ₹4,000
4th Renewed 03 Jun 2024 Period 03 May 2020 – 03 May 2021 · CBR 36595 · Certificate 108226 ₹4,000
5th Renewed 03 Jun 2024 Period 03 May 2021 – 03 May 2022 · CBR 36595 · Certificate 108227 ₹4,000
6th Renewed 03 Jun 2024 Period 03 May 2022 – 03 May 2023 · CBR 36595 · Certificate 108228 ₹4,000
7th Renewed 03 Jun 2024 Period 03 May 2023 – 03 May 2024 · CBR 36595 · Certificate 108229 ₹12,000
8th Renewed 03 Jun 2024 Period 03 May 2024 – 03 May 2025 · CBR 36595 · Certificate 108230 ₹12,000
9th Renewed 28 Apr 2025 Period 03 May 2025 – 03 May 2026 · CBR 25139 · Certificate 32411 ₹12,000